Efficacy in Japanese Adults With Growth Hormone Deficiency Receiving Weekly Somapacitan or Daily Growth Hormone: Results From Phase 3 REAL 1 Trial [PDF]
Frontiers in EndocrinologyIntroductionSomapacitan is a long-acting growth hormone (GH) derivative approved for once-weekly treatment of adult GH deficiency (AGHD). This study aimed to evaluate the efficacy and safety of somapacitan and daily GH in Japanese individuals with AGHD ...
Fumio Otsuka +2 more
exaly +4 more sources
Injection-site pain after switching from somatrogon to somapacitan in children reporting pain or discomfort during once-weekly growth hormone therapy: a prospective single-arm switch study [PDF]
Frontiers in EndocrinologyBackgroundOnce-weekly growth hormone (GH) formulations, such as somatrogon and somapacitan, may reduce the burden of treatment, but injection-site pain can affect treatment preference.
Hideyuki Iwayama +9 more
doaj +2 more sources
Long‐Acting Growth Hormone Versus Daily Growth Hormone for Growth Hormone Deficiency Patients: A Network Meta‐Analysis of Clinical Trials [PDF]
Endocrinology, Diabetes & MetabolismIntroduction Current guidelines recognize daily recombinant human growth hormone (rhGH) as standard care and long‐acting growth hormone (LAGH) as an alternative for paediatric growth hormone deficiency (CHD).
Amir Abadi +8 more
doaj +2 more sources
Weekly long-acting growth hormone versus daily growth hormone therapy on quality of life, efficacy, and safety in children with short stature: a systematic review and meta-analysis [PDF]
Frontiers in EndocrinologyBackgroundThis meta-analysis aims to compare the QoL, efficacy, and safety of once-weekly LAGH versus daily GH in children with short stature.MethodsWe systematically searched PubMed, Embase, the Cochrane Library, and Web of Science from inception to ...
Fan Liu +4 more
doaj +2 more sources
Frontiers in Endocrinology, 2022 Adult growth hormone deficiency (AGHD) is a rare endocrine disorder characterized by an abnormal body composition, metabolic abnormalities associated with increased cardiovascular diseases, bone loss, and impaired quality of life.
Jens Otto Lunde Jørgensen +2 more
exaly +3 more sources
Comparison of efficacy and safety between long-acting growth hormone and short-acting growth hormone in isolated growth hormone deficiency: a systematic review and meta-analysis of 16 randomized controlled trials involving 2,435 pediatric patients [PDF]
Frontiers in PediatricsObjectiveTo comprehensively compare the efficacy and safety of long-acting human growth hormone (LAGH) preparations with conventional short-acting daily growth hormone (SA-GH) in children with isolated growth hormone deficiency (GHD), and explore ...
Zhen-Zhen Shen +4 more
doaj +2 more sources
Usability and Preference Evaluation of the Somapacitan Pen-Injector and Lonapegsomatropin Autoinjector: Results of a US-Based Simulated-Use Study with Adolescent Patients and Caregivers [PDF]
Patient Preference and AdherenceJohan Medina,1 Gitte Ter-Borch,2 Nicky Kelepouris,3 Sophie Hamilton,3 Maya Gonczi,4 Jørgen Vinsløv Hansen,5 Shahid Akhtar1 1Medical & Science, Devices & Digital Health, Novo Nordisk A/S, Søborg, Denmark; 2Usability Engineering, Devices and Delivery ...
Medina J +6 more
doaj +2 more sources
New directions in growth hormone treatment in children [PDF]
Pediatric Endocrinology, Diabetes and MetabolismThis paper reviews clinical-trial evidence on the use of long-acting growth hormone (LAGH) preparations in children. Three LAGH products have been approved in Europe and the United States for paediatric growth hormone deficiency (GHD): lonapegsomatropin,
Renata Stawerska
doaj +2 more sources
Long-acting growth hormones: innovations in treatment and guidance on patient selection in pediatric growth hormone deficiency [PDF]
Annals of Pediatric Endocrinology & MetabolismLong-acting growth hormones (LAGHs) represent a significant advancement in the treatment of pediatric GH deficiency, offering an alternative to daily recombinant human GH (rhGH) therapy.
Chiara Rodaro +3 more
doaj +2 more sources
First 100 patients receiving long-acting growth hormone therapy: real-world evaluation from INSIGHTS-GHT registry [PDF]
Orphanet Journal of Rare DiseasesThe development of long-acting growth hormone (LAGH) formulations offers a promising approach to reduce injection frequency and to improve adherence in growth hormone deficiency (GHD) treatment.
Joachim Woelfle +5 more
doaj +2 more sources